Fabry_CEP: a tool to identify Fabry mutations responsive to pharmacological chaperones(320 views visite) Cammisa M, Correra A, Andreotti G, Cubellis MV
Dipartimento di Biologia, Universita Federico II, Napoli, Italy. Istituto di Chimica Biomolecolare -CNR, Pozzuoli, Italy Istituto di Biostrutture e Bioimmagini-CNR, Napoli, Italy
References Riferimenti: http://www.hgmd.cf.ac.uk/ac/index.php, HGMDGermain, D.P., Giugliani, R., Hughes, D.A., Mehta, A., Nicholls, K., Barisoni, L., Jennette, C.J., Sitaraman, S., Safety and pharmacodynamic effects of a pharmacological chaperone on alpha-galactosidase a activity and globotriaosylceramide clearance in fabry disease: Report from two phase 2 clinical studies (2012) Orphanet J Rare Dis, 7, p. 91. , 10.1186/1750-1172-7-91 2317661
Giugliani, R., Waldek, S., Germain, D.P., Nicholls, K., Bichet, D.G., Simosky, J.K., Bragat, A.C., Boudes, P.F., A phase 2 study of migalastat hydrochloride in females with fabry disease: Selection of population, safety and pharmacodynamic effects (2013) Mol Genet Metab, 109 (1), pp. 86-92. , 10.1016/j.ymgme.2013.01.009 23474038
Ishii, S., Pharmacological chaperone therapy for fabry disease (2012) Proceedings of the Japan Academy, 88 (1), pp. 18-30. , 10.2183/pjab.88.18
Cammisa, M., Correra, A., Andreotti, G., Cubellis, M.V., Identification and analysis of conserved pockets on protein surfaces (2013) BMC Bioinforma, 14 (SUPPL. 7)
Siekierska, A., De Baets, G., Reumers, J., Gallardo, R., Rudyak, S., Broersen, K., Couceiro, J., Rousseau, F., Alpha-galactosidase aggregation is a determinant of pharmacological chaperone efficacy on fabry disease mutants (2012) J Biol Chem, 287 (34), pp. 28386-28397. , 10.1074/jbc.M112.351056 22773828
Fernandez-Escamilla, A.-M., Rousseau, F., Schymkowitz, J., Serrano, L., Prediction of sequence-dependent and mutational effects on the aggregation of peptides and proteins (2004) Nature Biotechnology, 22 (10), pp. 1302-1306. , DOI 10.1038/nbt1012
Andreotti, G., Guarracino, M.R., Cammisa, M., Correra Cubellis, M.V., Prediction of the responsiveness to pharmacological chaperones: Lysosomal human alpha-galactosidase, a case of study (2010) Orphanet J Rare Dis, 5, p. 36. , 10.1186/1750-1172-5-36 21138548
http: //www. hgmd. cf. ac. uk/ac/index. php, HGMDGermain, D. P., Giugliani, R., Hughes, D. A., Mehta, A., Nicholls, K., Barisoni, L., Jennette, C. J., Sitaraman, S., Safety and pharmacodynamic effects of a pharmacological chaperone on alpha-galactosidase a activity and globotriaosylceramide clearance in fabry disease: Report from two phase 2 clinical studies (2012) Orphanet J Rare Dis, 7, p. 91. , 10. 1186/1750-1172-7-91 2317661
Fabry_CEP: a tool to identify Fabry mutations responsive to pharmacological chaperones
Fabry_CEP is a user-friendly web-application designed to help clinicians Choose Eligible Patients for the therapy with pharmacological chaperones. It provides a database and a predictive tool to evaluate the responsiveness of lysosomal alpha-galactosidase mutants to a small molecule drug, namely 1-Deoxy-galactonojirimycin. The user can introduce any missense/nonsense mutation in the coding sequence, learn whether it is has been tested and gain access to appropriate reference literature. In the absence of experimental data structural, functional and evolutionary analysis provides a prediction and the probability that a given mutation is responsive to the drug.
Fabry_CEP: a tool to identify Fabry mutations responsive to pharmacological chaperones
Kim YH, Shin SW, Pellicano R, Fagoonee S, Choi IJ, Kim YI, Park B, Choi JM, Kim SG, Choi J, Park JY, Oh S, Yang HJ, Lim JH, Im JP, Kim JS, Jung HC, Ponzetto A, Figura N, Malfertheiner P, Choi IJ, Kook MC, Kim YI, Cho SJ, Lee JY, Kim CG, Park B, Nam BH, Bae SE, Choi KD, Choe J, Kim SO, Na HK, Choi JY, Ahn JY, Jung KW, Lee J, Kim DH, Chang HS, Song HJ, Lee GH, Jung HY, Seta T, Takahashi Y, Noguchi Y, Shikata S, Sakai T, Sakai K, Yamashita Y, Nakayama T, Leja M, Park JY, Murillo R, Liepniece-karele I, Isajevs S, Kikuste I, Rudzite D, Krike P, Parshutin S, Polaka I, Kirsners A, Santare D, Folkmanis V, Daugule I, Plummer M, Herrero R, Tsukamoto T, Nakagawa M, Kiriyama Y, Toyoda T, Cao X, Corral JE, Mera R, Dye CW, Morgan DR, Lee YC, Lin JT, Garcia Martin R, Matia Cubillo A, Lee SH, Park JM, Han YM, Ko WJ, Hahm KB, Leontiadis GI, Ford AC, Ichinose M, Sugano K, Jeong M, Park JM, Han YM, Park KY, Lee DH, Yoo JH, Cho JY, Hahm KB, Bang CS, Baik GH, Shin IS, Kim JB, Suk KT, Yoon JH, Kim YS, Kim DJ * Helicobacter pylori Eradication for Prevention of Metachronous Recurrence after Endoscopic Resection of Early Gastric Cancer(204 visite) N Engl J Med (ISSN: 0028-4793, 0028-4793linking, 1533-4406electronic), 2015 Jun; 30642104201566393291: 749-756. Impact Factor:59.558 DettagliEsporta in BibTeXEsporta in EndNote
Hesse B, Tagil K, Cuocolo A, Anagnostopoulos C, Bardies M, Bax J, Bengel F, Busemann Sokole E, Davies G, Dondi M, Edenbrandt L, Franken P, Kjaer A, Knuuti J, Lassmann M, Ljungberg M, Marcassa C, Marie PY, Mckiddie F, O'connor M, Prvuolovich E, Underwood R * 3. 0 T perfusion MR imaging(535 visite) Rivista Di Neuroradiologia (ISSN: 1120-9976), 2004; 17(6): 807-812. Impact Factor:0.023 DettagliEsporta in BibTeXEsporta in EndNote
Testino G, Leone S, Fagoonee S, Del Bas JM, Rodriguez B, Puiggros F, Marine S, Rodriguez MA, Morina D, Armengol L, Caimari A, Arola L, Cimini FA, Barchetta I, Carotti S, Bertoccini L, Baroni MG, Vespasiani-gentilucci U, Cavallo MG, Morini S, Nelson JE, Roth CL, Wilson LA, Yates KP, Aouizerat B, Morgan-stevenson V, Whalen E, Hoofnagle A, Mason M, Gersuk V, Yeh MM, Kowdley KV, Lee SM, Jun DW, Cho YK, Jang KS, Kucukazman M, Ata N, Dal K, Yeniova AO, Kefeli A, Basyigit S, Aktas B, Akin KO, Agladioglu K, Ure OS, Topal F, Nazligul Y, Beyan E, Ertugrul DT, Catena C, Cosma C, Camozzi V, Plebani M, Ermani M, Sechi LA, Fallo F, Goto Y, Ray MB, Mendenhall CL, French SW, Gartside PS Serum vitamin A deficiency and increased intrahepatic expression of cytokeratin antigen in alcoholic liver disease(418 visite) Hepatology (ISSN: 1827-1669electronic, 0026-4806linking), 1988 Sep; 83120693611123109(5): 1019-1026. Impact Factor:0.913 DettagliEsporta in BibTeXEsporta in EndNote
528 Records (509 escludendo Abstract e Conferenze). Impact factor totale: 1985.22 (1914.684 escludendo Abstract e Conferenze). Impact factor a 5 anni totale: 1996.045 (1913.371 escludendo Abstract e Conferenze).
Last modified by Ultima modifica di Marco Comerci on in data Sunday 12 July 2020, 13:14:53 320 views visite. Last view on Ultima visita in data Friday 18 December 2020, 13:09:34